How were Nemus Bioscience's earnings last quarter?

Nemus Bioscience Inc (OTCMKTS:NMUS) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter.

What other stocks do shareholders of Nemus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF) , KushCo (KSHB) , MedMen Enterprises (MMNFF) , Aurora Cannabis (ACBFF) , CannaRoyalty (ORHOF) , Unrivaled Brands (TRTC) , BOTS (MCIG) and Cronos Group (CRON) .

How do I buy shares of Nemus Bioscience?

Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:NMUS

Nemus Bioscience (NMUS) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NMUS Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $3.69
▼
$17.75
52-Week Range: N/A

Volume: 1.00 million shs
Average Volume: 377,395 shs
Market Capitalization: $87.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Nemus Bioscience alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Nemus Bioscience Stock (OTCMKTS:NMUS)

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

NMUS Stock News Headlines

April 19, 2024 | finance.yahoo.com

Yield10 Bioscience, Inc. (YTEN)

March 16, 2024 | morningstar.com

Assembly Biosciences Inc ASMB

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 5, 2023 | money.usnews.com

Sagimet Biosciences Inc - Ordinary Shares - Class A

April 27, 2023 | finance.yahoo.com

Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures

April 6, 2023 | finanznachrichten.de

Crown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting Biobank

February 24, 2023 | finance.yahoo.com

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

January 27, 2023 | finance.yahoo.com

SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

January 27, 2023 | yahoo.com

Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

January 27, 2023 | finance.yahoo.com

Renaissance BioScience Corp. and Timeless Capital Corp. Enter into Letter of Intent

October 26, 2022 | finance.yahoo.com

BioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital Health

September 23, 2022 | finance.yahoo.com

Neurocrine Biosciences, Inc. (NBIX)

See More Headlines

Receive NMUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: N/A
Sub-Industry: Cannabis
Current Symbol: OTCMKTS:NMUS
CUSIP: N/A
CIK: N/A
Web: www.nemusbioscience.com
Phone: 949-396-0330
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -924.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.12
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 133,908,000
Free Float: N/A
Market Cap: $87.04 million
Optionable: Not Optionable
Beta: -0.04

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Brian S. Murphy (Age 61)
CEO, Chief Medical Officer & Director
Dr. Avtar S. Dhillon (Age 57)
Exec. Chairman
Mr. Douglas A. Cesario (Age 44)
Chief Financial Officer
Ms. Wendy Cunning
VP of Bus. Operations

Key Competitors

View All Competitors

NMUS Stock Analysis - Frequently Asked Questions

How were Nemus Bioscience's earnings last quarter?: Nemus Bioscience Inc (OTCMKTS:NMUS) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter.
What other stocks do shareholders of Nemus Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF), KushCo (KSHB), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Unrivaled Brands (TRTC), BOTS (MCIG) and Cronos Group (CRON).
How do I buy shares of Nemus Bioscience?: Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NMUS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nemus Bioscience (NMUS) Stock Price, News & Analysis

About Nemus Bioscience Stock (OTCMKTS:NMUS)

NMUS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NMUS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info